Scopus BioPharma (SCPS) Short Interest Ratio & Short Volume $0.0003 0.00 (0.00%) As of 06/3/2025 Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock Scopus BioPharma Short Interest DataScopus BioPharma (SCPS) has a short interest of 10,500 shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 52.5, indicating that it would take 52.5 days of the average trading volume of 2,056 shares to cover all short positions.Current Short Interest10,500 sharesPrevious Short Interest10,500 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$3.15Short Interest Ratio52.5 Days to CoverLast Record DateMay 15, 2025Outstanding Shares42,084,000 sharesPercentage of Shares Shorted0.02%Today's Trading Volume1 sharesAverage Trading Volume2,056 sharesToday's Volume Vs. Average0% Short Selling Scopus BioPharma? Sign up to receive the latest short interest report for Scopus BioPharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSCPS Short Interest Over TimeSCPS Days to Cover Over TimeSCPS Percentage of Float Shorted Over Time Scopus BioPharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202510,500 shares $3.15 No ChangeN/A52.5 $0.00 4/30/202510,500 shares $3.15 No ChangeN/A0 $0.00 4/15/202510,500 shares $3.15 No ChangeN/A5.3 $0.00 3/14/202510,500 shares $3.15 No ChangeN/A3.2 $0.00 2/14/202510,500 shares $3.15 No ChangeN/A35 $0.00 1/31/202510,500 shares $3.15 No ChangeN/A7.5 $0.00 1/15/202510,500 shares $3.15 No ChangeN/A2 $0.00 12/15/202260,400 shares $20,542.04 +153.8%0.8%0.1 $0.34 11/30/202223,800 shares $5,240.76 -38.0%0.3%0.1 $0.22 11/15/202238,400 shares $9,411.84 +96.9%0.5%0.1 $0.25 Get the Latest News and Ratings for SCPS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Scopus BioPharma and its competitors with MarketBeat's FREE daily newsletter. 10/31/202219,500 shares $4,910.10 -21.1%0.3%0.1 $0.25 10/15/202224,700 shares $6,034.21 -39.8%0.3%0.1 $0.24 9/30/202241,000 shares $9,926.10 +215.4%0.6%0.5 $0.24 9/15/202213,000 shares $4,075.50 +282.4%0.2%0.1 $0.31 8/31/20223,400 shares $1,180.48 -88.3%0.1%0 $0.35 8/15/202229,100 shares $12,804.00 +62.6%0.4%0.4 $0.44 7/31/202217,900 shares $6,794.84 -3.8%0.3%0.3 $0.38 7/15/202218,600 shares $6,986.16 -65.6%0.3%0.3 $0.38 6/30/202254,100 shares $23,263.00 -70.1%0.8%0.8 $0.43 6/15/2022180,800 shares $72,555.04 +80.8%2.5%2.1 $0.40 5/31/2022100,000 shares $39,430.00 +82.5%1.4%0.4 $0.39 5/15/202254,800 shares $22,468.00 -39.4%0.8%0.2 $0.41 4/30/202290,400 shares $43,663.20 +7.9%1.3%0.3 $0.48 4/15/202283,800 shares $54,335.84 +11.4%1.2%0.3 $0.65 3/31/202275,200 shares $51,970.72 -23.7%1.1%0.2 $0.69 3/15/202298,600 shares $61,171.44 +282.2%1.4%0.3 $0.62 2/28/202225,800 shares $18,705.00 -65.4%0.4%0.2 $0.73 2/15/202274,600 shares $63,037.00 +20.3%1.0%0.7 $0.85 1/31/202262,000 shares $70,060.00 -15.3%1.3%0.8 $1.13 1/15/202273,200 shares $101,748.00 +11.6%1.8%0.9 $1.39 12/31/202165,600 shares $107,256.00 +1.7%1.6%0.8 $1.64 12/15/202164,500 shares $127,710.00 +5.2%1.6%0.7 $1.98 11/30/202161,300 shares $152,024.00 -21.6%1.5%0.6 $2.48 11/15/202178,200 shares $275,264.00 -9.6%1.8%0.3 $3.52 10/29/202186,500 shares $292,370.00 -21.2%2.0%0.3 $3.38 10/15/2021109,700 shares $437,703.00 -7.9%2.5%0.2 $3.99 9/30/2021119,100 shares $494,265.00 +88.2%2.7%0.3 $4.15 9/15/202163,300 shares $363,975.00 -16.7%1.5%0.1 $5.75 8/31/202176,000 shares $417,240.00 -19.7%5.6%0.2 $5.49 8/13/202194,600 shares $428,538.00 +266.7%3.3%0.1 $4.53Why July 22nd Could Mean Big Changes for Social Security (Ad)In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22. What's coming next isn't about trimming waste.To see the full playbook and how it could impact everyone, click here. 7/30/202125,800 shares $119,970.00 -52.4%0.6%0 $4.65 7/15/202154,200 shares $307,856.00 -6.9%1.2%0.1 $5.68 6/30/202158,200 shares $415,548.00 -56.8%1.0%0.1 $7.14 6/15/2021134,700 shares $961,758.00 -34.7%2.4%0.2 $7.14 5/28/2021206,400 shares $1.46 million +47.9%3.7%0.2 $7.08 5/14/2021139,600 shares $721,732.00 +26.2%2.5%0.2 $5.17 4/30/2021110,600 shares $843,878.00 +26.4%1.7%1 $7.63 4/15/202187,500 shares $684,250.00 +74.0%1.2%0.6 $7.82 3/31/202150,300 shares $399,382.00 +74.1%0.8%0.3 $7.94 3/15/202128,900 shares $279,174.00 +228.4%0.3%0.1 $9.66 2/26/20218,800 shares $77,264.00 +51.7%0.1%0 $8.78 2/12/20215,800 shares $57,130.00 -96.5%0.1%0 $9.85 1/29/2021164,900 shares $1.65 million +937.1%1.5%0.3 $10.02 1/15/202115,900 shares $206,223.00 No Change0.2%0 $12.97 SCPS Short Interest - Frequently Asked Questions What is Scopus BioPharma's current short interest? Short interest is the volume of Scopus BioPharma shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 10,500 shares of SCPS short. Learn More on Scopus BioPharma's current short interest. What is a good short interest ratio for Scopus BioPharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SCPS shares currently have a short interest ratio of 52.0. Learn More on Scopus BioPharma's short interest ratio. Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Scopus BioPharma stock? Short selling SCPS is an investing strategy that aims to generate trading profit from Scopus BioPharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Scopus BioPharma? A short squeeze for Scopus BioPharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SCPS, which in turn drives the price of the stock up even further. How often is Scopus BioPharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SCPS, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies Alvotech Short Squeeze BriaCell Therapeutics Short Squeeze Clene Short Squeeze enGene Short Squeeze Fortress Biotech Short Squeeze Immatics Short Squeeze Jasper Therapeutics Short Squeeze Lexaria Bioscience Short Squeeze Lixte Biotechnology Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SCPS) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Scopus BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
